Celgene Corporation - VAI
FDA Inspections Database
Celgene Corporation - VAI
FDA Inspections Database
U.S. FDA inspection classifications and citation records from the official FDA inspection database.
- Total Records 11
- Latest Inspection 2025-07-18
- Data Source U.S. FDA
- Last Updated 2026-02-10
Company Overview
Social Profiles
Company Snapshot
FDA Inspections Timeline (11 records)
Legal Name
Celgene Corporation
Project Area
Human Cellular, Tissue, and Gene Therapies
Product Type
Biologics
Posted Citations
No
Inspection End Date
2025-07-18
FMD Date
2026-02-10
Fiscal Year
2025
State
New Jersey
Location
Summit, New Jersey, United States
Inspection Info
Fiscal Year: 2025
Citations: No
Legal Name
Celgene Corporation
Project Area
Bioresearch Monitoring
Product Type
Drugs
Posted Citations
Yes
Inspection End Date
2024-12-06
FMD Date
2025-03-04
Fiscal Year
2025
State
New Jersey
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)
Location
Summit, New Jersey, United States
Inspection Info
Fiscal Year: 2025
Citations: Yes
Legal Name
Celgene Corporation
Project Area
Human Cellular, Tissue, and Gene Therapies
Product Type
Biologics
Posted Citations
Yes
Inspection End Date
2023-06-16
FMD Date
2023-11-08
Fiscal Year
2023
State
New Jersey
Location
Summit, New Jersey, United States
Inspection Info
Fiscal Year: 2023
Citations: Yes
Legal Name
Celgene Corporation
Project Area
Bioresearch Monitoring
Product Type
Drugs
Posted Citations
No
Inspection End Date
2015-08-04
FMD Date
-
Fiscal Year
2015
State
New Jersey
Additional Details
Postmarket Adverse Drug Experience (PADE)
Location
Berkeley Heights, New Jersey, United States
Inspection Info
Fiscal Year: 2015
Citations: No
Legal Name
Celgene Corporation
Project Area
Postmarket Surv. and Epidemiology
Product Type
Drugs
Posted Citations
No
Inspection End Date
2015-08-04
FMD Date
-
Fiscal Year
2015
State
New Jersey
Location
Berkeley Heights, New Jersey, United States
Inspection Info
Fiscal Year: 2015
Citations: No
Legal Name
Celgene Corporation
Project Area
Bioresearch Monitoring
Product Type
Drugs
Posted Citations
Yes
Inspection End Date
2013-04-24
FMD Date
-
Fiscal Year
2013
State
New Jersey
Additional Details
Postmarket Adverse Drug Experience (PADE)
Location
Berkeley Heights, New Jersey, United States
Inspection Info
Fiscal Year: 2013
Citations: Yes
Legal Name
Celgene Corporation
Project Area
Bioresearch Monitoring
Product Type
Drugs
Posted Citations
Yes
Inspection End Date
2012-09-12
FMD Date
-
Fiscal Year
2012
State
New Jersey
Additional Details
Sponsor, Contract Research Organization
Location
Berkeley Heights, New Jersey, United States
Inspection Info
Fiscal Year: 2012
Citations: Yes
Legal Name
Celgene Corporation
Project Area
Drug Quality Assurance
Product Type
Drugs
Posted Citations
No
Inspection End Date
2012-07-30
FMD Date
-
Fiscal Year
2012
State
New Jersey
Location
Summit, New Jersey, United States
Inspection Info
Fiscal Year: 2012
Citations: No
Legal Name
Celgene Corporation
Project Area
Bioresearch Monitoring
Product Type
Drugs
Posted Citations
Yes
Inspection End Date
2011-08-25
FMD Date
-
Fiscal Year
2011
State
New Jersey
Additional Details
Postmarket Adverse Drug Experience (PADE)
Location
Berkeley Heights, New Jersey, United States
Inspection Info
Fiscal Year: 2011
Citations: Yes
Legal Name
Celgene Corporation
Project Area
Drug Quality Assurance
Product Type
Drugs
Posted Citations
Yes
Inspection End Date
2010-03-19
FMD Date
-
Fiscal Year
2010
State
New Jersey
Location
Summit, New Jersey, United States
Inspection Info
Fiscal Year: 2010
Citations: Yes
Legal Name
Celgene Corporation
Project Area
Bioresearch Monitoring
Product Type
Drugs
Posted Citations
Yes
Inspection End Date
2009-09-03
FMD Date
-
Fiscal Year
2009
State
New Jersey
Additional Details
Postmarket Adverse Drug Experience (PADE)
Location
Summit, New Jersey, United States
Inspection Info
Fiscal Year: 2009
Citations: Yes
Classification Breakdown
11 total- VAI (Voluntary Action Indicated)
Official Source
All data is sourced from the official FDA inspection database maintained by the U.S. Food and Drug Administration.
Visit FDA.govRecord Details Preview
Click "View Details" on any record above to expand full details inline.
Location
Summit, New Jersey, United States
Inspection Info
Fiscal Year: 2025
Citations: No
100% Official Data
Directly from the U.S. FDA inspection database
Regular Updates
Data updated regularly from official sources
Trusted by Professionals
100K+ pharma professionals worldwide
Secure & Reliable
Enterprise-grade security and data protection
Create a New Buying Request
Fields marked with * are mandatory.